CD44 and urinary bladder neoplasm: Overall glycoproteogenomics analysis of different cell models and bladder tumors supported transcriptomics data and provided a mass spectrometry-based approach for validation of several CD44 exon-exon junctions, moving one step forward in the characterization of this glycoprotein.